Literature DB >> 15505756

Global risk management in type 2 diabetes: blood glucose, blood pressure, and lipids--update on the background of the current guidelines.

A Clemens1, E Siegel, B Gallwitz.   

Abstract

Diabetes mellitus presents a significant public health burden based on its increased morbidity, mortality, and economic cost. The high comorbidity and prevalence of concomitant diseases like hypertension and dyslipidemia in diabetic patients cause the high risk in developing secondary, cost intensive, and for the patient often disastrous late complications (nephropathy, retinopathy, neuropathy, and cardiovascular disease). Therefore, patients with diabetes mellitus need a global risk management that takes the various individual clinical problems into account. The current global standards of therapy in patients with diabetes mellitus are focused on the control of glycemia, blood pressure, and lipid levels, as well as aspirin therapy and avoiding of smoking. There are a number of guidelines and recommendations to manage these global issues. Our review will summarize current recommendations and consolidate therapeutic goals and treatments that are of vital importance in the global risk management in diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15505756     DOI: 10.1055/s-2004-821306

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  14 in total

1.  Long-chain acyl coenzyme A synthetase 1 overexpression in primary cultured Schwann cells prevents long chain fatty acid-induced oxidative stress and mitochondrial dysfunction.

Authors:  Lucy M Hinder; Claudia Figueroa-Romero; Crystal Pacut; Yu Hong; Anuradha Vivekanandan-Giri; Subramaniam Pennathur; Eva L Feldman
Journal:  Antioxid Redox Signal       Date:  2013-10-05       Impact factor: 8.401

Review 2.  Hyperlipidemia: a new therapeutic target for diabetic neuropathy.

Authors:  Andrea M Vincent; Lucy M Hinder; Rodica Pop-Busui; Eva L Feldman
Journal:  J Peripher Nerv Syst       Date:  2009-12       Impact factor: 3.494

Review 3.  Neurological consequences of obesity.

Authors:  Phillipe D O'Brien; Lucy M Hinder; Brian C Callaghan; Eva L Feldman
Journal:  Lancet Neurol       Date:  2017-06       Impact factor: 44.182

4.  Apolipoprotein E knockout as the basis for mouse models of dyslipidemia-induced neuropathy.

Authors:  Lucy M Hinder; Andrea M Vincent; John M Hayes; Lisa L McLean; Eva L Feldman
Journal:  Exp Neurol       Date:  2012-10-08       Impact factor: 5.330

Review 5.  Diabetic neuropathy: clinical manifestations and current treatments.

Authors:  Brian C Callaghan; Hsinlin T Cheng; Catherine L Stables; Andrea L Smith; Eva L Feldman
Journal:  Lancet Neurol       Date:  2012-05-16       Impact factor: 44.182

6.  Exenatide.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial.

Authors:  J W J Beulens; A Patel; J R Vingerling; J K Cruickshank; A D Hughes; A Stanton; J Lu; S A McG Thom; D E Grobbee; R P Stolk
Journal:  Diabetologia       Date:  2009-07-25       Impact factor: 10.122

Review 8.  Vildagliptin: a review of its use in the management of type 2 diabetes mellitus.

Authors:  Jamie D Croxtall; Susan J Keam
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Chewing the fat: genetic approaches to model dyslipidemia-induced diabetic neuropathy in mice.

Authors:  B L Guilford; D E Wright
Journal:  Exp Neurol       Date:  2013-08-08       Impact factor: 5.330

Review 10.  Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea).

Authors:  Risto S Cvetković; Greg L Plosker
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.